- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01869491
Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study
May 12, 2014 updated by: Reckitt Benckiser Healthcare (UK) Limited
A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease
This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with Gastroesophageal Reflux Disease (GERD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1107
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- RB Investigational Sites
-
Shanghai, China
- RB Investigational Sites
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Current evidence of symptomatic GERD in accord with the Montreal definition
- Patients must have had troublesome heartburn and/or regurgitation (with or without dyspepsia symptoms) of at least mild or moderate intensity on at least five days during the week before the start of screening
Exclusion Criteria:
- Patients who have a history of drug, solvent or alcohol abuse
- Patients who have suffered cardiac chest pain within the last year.
- Patients who have suffered a recent, significant unexplained weight loss of more than 6 Kg in the last 6 months.
- Female patients of childbearing potential who, for the duration of the study, are either unwilling or unable to take adequate contraceptive precautions or are unwilling to be sexually abstinent
- Pregnancy or lactating mother.
- Patients with a history and/or symptom profile and/or discovered on endoscopy suggestive of the following: any other gastrointestinal (GI) disease, erosive GERD (Los Angeles [LA] classification grades C-D), Barrett's esophagus, acute peptic ulcer and/or ulcer complications, Zollinger-Ellison syndrome, gastric carcinoma, pyloric stenosis, oesophageal or gastric surgery, intestinal obstruction, current pernicious anaemia, indication for H-pylori eradication therapy, known gastro-intestinal bleeding (hematochezia or hematemesis) within the last 3 months, and severe diseases of other major body systems.
- Patients who were observed on endoscopy to have a hiatus hernia with a diameter which exceeds 3cm.
- Patients who have taken anti-cholinesterase drugs, traditional Chinese medicines for treating gastrointestinal disease, ulcermin or misoprostol preparations within 7 days prior to screening or throughout the study.
- Patients who have taken PPIs during the 10 days prior to screening, prokinetics or H2 antagonists during the 5 days prior to screening or systemic glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs, except for low dose aspirin which can be given for cardioprotection) on more than 3 consecutive days or PPI-based triple or quadruple therapy for eradication of H-pylori during the last 28 days.
- Patients taking or requiring to take macrolide antibiotics, such as erythromycin, azithromycin, from the day before screening.
- Patients with known hypophosphataemia, phenylketonuria or hypercalcaemia.
- Patients with severe constipation, or history of intestinal obstruction.
- In the opinion of the Investigator, patients with damaged heart or kidney diseases and patients who require a low sodium diet.
- Any previous history of allergy or known intolerance to any of the IMP's
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sodium Alginate Double Action Tablets
Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily
|
2 tablets four times daily
Other Names:
|
Placebo Comparator: Matching placebo tablets
Matching placebo tablets, 2 tablets four times daily
|
2 tablets four times daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in GERD dimension
Time Frame: 7 days
|
The primary study endpoint is to compare the change from baseline in RDQ symptom scores for the GERD dimension (heartburn and regurgitation) after a 7-day treatment period of Compound Sodium Alginate Double Action Chewable Tablets compared with a matched placebo
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in RDQ scores for dyspepsia dimension
Time Frame: 7 days
|
Comparison between the two cohorts (Compound Sodium Alginate Double Action Chewable Tablets and matching placebo) for a 7-day treatment period for change from baseline in RDQ scores for dyspepsia dimension
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yuan Yaozong, MD, PhD, Shanghai Jiaotong University, School of Medicine, Shanghai, China
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
May 31, 2013
First Submitted That Met QC Criteria
June 4, 2013
First Posted (Estimate)
June 5, 2013
Study Record Updates
Last Update Posted (Estimate)
May 13, 2014
Last Update Submitted That Met QC Criteria
May 12, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Signs and Symptoms, Digestive
- Gastrointestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Dyspepsia
- Gastroesophageal Reflux
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Antacids
- Alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination
Other Study ID Numbers
- GA1210
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspepsia
-
King Chulalongkorn Memorial HospitalRecruiting
-
Wuhan Central HospitalNot yet recruiting
-
Dong-A ST Co., Ltd.Not yet recruitingFunctional DyspepsiaKorea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Zeria PharmaceuticalRecruitingFunctional DyspepsiaJapan
-
Hong Kong Baptist UniversityXiyuan Hospital of China Academy of Chinese Medical SciencesRecruitingFunctional DyspepsiaHong Kong
-
Seoul National University HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Wonju Severance Christian HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedFunctional DyspepsiaKorea, Republic of
Clinical Trials on Compound Sodium Alginate Double Action Chewable Tablets
-
Reckitt Benckiser Healthcare (UK) LimitedCompletedGastroesophageal Reflux DiseaseChina
-
Reckitt Benckiser Healthcare (UK) LimitedCompletedGastro-esophageal Reflux Disease (GERD)China
-
Reckitt Benckiser Healthcare (UK) LimitedTerminatedGastro-esophageal Reflux Disease (GERD)China
-
Peking Union Medical College HospitalUnknownLactate | Severe Sepsis With Septic Shock
-
Torrent Pharmaceuticals LimitedCompleted
-
Torrent Pharmaceuticals LimitedCompleted
-
Cairo UniversityUnknownPlaque | Saliva AlteredEgypt
-
Eisai Co., Ltd.Completed